Clinicopathological and molecular mechanisms of CLDN18.2 in gastric cancer aggressiveness: a high-risk population study with multi-omics profiling
CLDN18.2 overexpression is associated with poor prognosis in GC patients. Transcriptomic and proteomic analyses demonstrate that CLDN18.2 promotes tumor progression and metastasis, underscoring its potential as an independent prognostic factor in regions with a high incidence of GC.
Authors
- P Zhang
- T. Liu
- Peiqing Liao
- Gang Wang
- Luxi Yang
- Wenting He
- Yumin Li
- Mei Li
- Hengquan Wu
Institutions
- Translational Research in Oncology (FR)
- Lanzhou University Second Hospital (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Journal of Pathology and Translational Medicine
- Published
- 2026-01-05
- DOI
- https://doi.org/10.4132/jptm.2025.09.11
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00